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Background: The treatment of human cancer has been seriously hampered for decades by resistance to
chemotherapeutic drugs. A very efficient mechanism of tumor resistance to drugs is the proton pumps-mediated
acidification of tumor microenvironment. Metronomic chemotherapy has shown efficacy in adjuvant fashion as well
as in the treatment of pets with advanced disease. Moreover, we have shown in veterinary clinical settings that
pre-treatment with proton-pumps inhibitors (PPI) increases tumor responsiveness to chemotherapeutics. In this
study pet with spontaneously occurring cancer have been recruited to be treated by a combination of metronomic
chemotherapy and high dose PPIs and their responses have been matched to those of a historical control of ten
patients treated with metronomic chemotherapy alone.
Methods: Single arm, non randomized phase II open study, with historical control group, evaluating safety and
efficacy of the combination of metronomic chemotherapy and alkalization. Twenty-four companion animals
(22 dogs and 2 cats) were treated adding to their metronomic chemotherapy protocol the pump inhibitor
lansoprazole at high dose, and a water alkalizer. Their responses have been evaluated by clinical and instrumental
evaluation and matched to those of the control group.
Results: The protocol was overall well tolerated, with only two dogs experiencing side effects due to gastric
hypochlorhydria consisting with vomiting and or diarrhea. In terms of overall response, in the alkalized cohort,
18 out of 24 had partial or complete responses (75%), two patients had a stable disease and the remaining patients
experienced no response or progressive disease. On the other hand, only one patient in the control group
experienced a complete response (10%) and three other experienced short lived responses. Median time to
terminal event was 34 weeks for the experimental group versus 2 weeks in the controls (p= 0.042).
Conclusions: Patient alkalization has shown to be well tolerated and to increase tumor response to metronomic
chemotherapy as well the quality of life in pets with advanced cancer. Further studies are warranted to assess the
efficacy of this strategy in patients with advanced cancers in companion animals as well as in humans.
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Cancer initiation, invasion and dissemination are dynamic
phenomena influenced by tumor microenvironment and
host factors. Standard anticancer drugs were devised ac-
cordingly to Erlich’s magic bullet concept and rely on their
capacity to directly kill malignant cells. In the attempt to
maximize their efficacy, they are administered at a maximal
tolerated dose (MTD), the highest amount of the drug asso-
ciated with tolerable toxicity and manageable side effects
[1,2]. As a consequence of this approach, patients must go
through long periods off therapy, allowing for their full re-
covery from the adverse effects of chemotherapy. These
interruptions, however, also permit cancer cells to become
resistant to chemotherapy and hence to promote a disease
recurrence [3,4]. As a consequence, despite the discovery of
a significant number of these drugs and the huge number
of clinical trials that have been undertaken to develop novel
multi-drugs protocols, results has been modest in terms of
cure or life extension of cancer patients, especially those
with advanced-stage or metastatic disease [5]. A new thera-
peutic paradigm has recently been devised, consisting of
the use of low-dose chemotherapeutics at short intervals
(so-called, metronomic chemotherapy), in the absence of
extended drug-free periods [6,7]. Metronomic chemother-
apy is not only almost devoid of toxic effects, but also ex-
erts e direct citotoxicity combined with an antiangiogenic
activity resulting in significant efficacy [8,9]. Several studies
in human and veterinary oncology have shown efficacy of
low dose alkylating agents such as cyclophosphamide and
chlorambucil to directly approach refractory cancers or as
adjuvant therapy for highly metastatic or metastasizing
tumor [10-17]. The other factor to be taken into account
when planning a treatment procotol, is the response to
chemotherapy by tumor cells. This depends on the con-
centration of cytostatics accumulated within the cells,
phenomenon that is dependent on functional expression
of efflux transporters, but also on the pH of extracellular
microenvironment. In fact, the acidity of tumor microenvir-
onment is a key factor in the low level of responsiveness of
tumor cells to chemotherapeutics, and proton exchangers
have a crucial impact in extracellular acidification of cancer
cells [18,19]. Tumor cells rely on H+ exchangers, in particu-
lar the vacuolar H+-ATPases (V-ATPases) to dispose of
the dangerous protons byproduct of cancer metabolism
[20-22]. The acidic tumor environment is a consequence of
anaerobic glucose metabolism resulting in accumulation of
acids such as lactates, leading to enhanced transmembrane
pH regulation [22]. These proton pumps, together with
other ion exchangers, play a crucial function in the estab-
lishment and maintenance of cancer microenvironment
and their action results in the selection of more aggressive
cell phenotypes able to survive in this highly hostile micro-
environment, with a key role in the establishment and
maintenance of chemoresistance [19]. There are severalproposed mechanisms involved in this phenomenon,
including decreased uptake or neutralization of weakly
basic drugs by the acidic tumor microenvironment or the
confinement of chemotherapy drugs within lysosomal
vesicles [23]. An accelerated turnover of acidic vesicles
may represent an additional tumor strategy of drug resist-
ance based on counteracting current transportation [24].
Recently, a role of nanovesicles (exosomes) released by re-
sistant cancer cells has been in elimination of tumor drug
such as cisplatin, and extracellular acidity and exosomes
release belong to a framework exerting a central role of
malignant cancer unresponsiveness to chemotherapy [25].
Interestingly, the expression of proton pumps is increased
in chemoresistant phenotypes and further increased by
anticancer drugs as well [24]. Proton pump inhibitors have
been shown to be highly effective in inhibiting V-ATPases
in vitro and well tolerated and effective in murine models,
improving response to chemotherapy and tumor control
[24]. Moreover, in a previous study, our group showed
that high dose of the proton pump inhibitor lansoprazole
could reverse chemoresistance in a cohort of pets affected
by spontaneous chemoresistant neoplasms, obtaining an
high percentage of responders with minimal toxicities
[26]. A recent clinical study in osteosarcoma patients has
shown a clear effectiveness of PPI in increasing the effect-
iveness of standard chemotherapy, particularly in those
patients that show low level of responsiveness to the
standard protocols [27]. Thus, the ensemble of these
studies, but also the evidence that a systemic buffering ap-
proach may represent a useful new strategy in both pre-
venting [28] and in treating [29] cancer, suggested that a
therapy combining different anti-acidic approaches, may
represent a real new path in the war against cancer. Thus,
the aim of this study was to investigate the feasibility,
tolerability and efficacy of high dose proton pump inhibi-
tor lansoprazole combined with water alkalization within
a metronomic protocol in companion animals affected by
advanced or highly metastatic neoplasms.
Methods
Patient selection
Privately owned canine and feline patients with advanced
or highly metastatic neoplasms were selected for the
study. Due to the advanced stage of the disease and the
poor response to standard chemotherapy, the owners were
offered two options: a) palliative therapy b) metronomic
chemotherapy with the addition of high dose lansoprazole
and water alkalization. Their responses have been matched
against those of an historical group of 10 pets treated with
metronomic chemotherapy alone.
Previous informed consent was obtained from the
owners. In order to be enrolled in the study, according
to the Italian law (116/92) and the guidelines defined by
the ethical committee of the National Cancer Institute


















2 Anorexia ≤3 days duration
3 Anorexia >3 days but <5 days





3 1–5 episodes per day, <2 days
4 6–10 episodes per day, hospitalized
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ing to the World Health Organization (WHO) grading
system, were considered eligible if they fulfilled the fol-
lowing criteria:
1. Normal renal function (normal serum blood urea
nitrogen [BUN], creatinine, phosphorus, and urine
specific gravity).
2. Absence of underlying life threatening diseases or
other medical complications (e.g. diabetes mellitus).
3. Compliance of the owner for follow-up rechecks.
4. A presumptive life expectancy of at least four weeks.
5. Overall performance status assessed according to the
modified Karnowsky system, had to be less than 3
(Table 1).
Staging process included a thorough anamnesis, physical
examination, caliper or ultrasonographic measurement of
the neoplasm, complete blood cell count (CBC), serum
biochemistry profile, thoracic radiographs (three projections:
two laterals and one ventro-dorsal), and abdominal
ultrasonography. In order to confirm the diagnoses,
histological re-examination of the biopsies were performed




Dogs and cats with advanced or highly metastaic spon-
taneous neoplasms or with chemoresistant tumors
were treated with lansoprazole at the dose of 5 mg/kg
from Monday through Wednesday and 1 mg/kg from
Thursday to Sunday, combined with metronomic chemo-
therapy and a commercially available water alkalizer
(alka water) added to mineral waters having pH between
7.8 and 8.0 to bring the final water pH to 9. Metronomic
chemotherapy consisted with daily cyclophosphamide at
the dose of 12.5 mg/m2, and piroxicam at the dose of
0.3 mg/kg and was the same for the experimental cohort
and the historical controls [12]. Cats were treated withTable 1 Modified Kamofsky’s performance criteria
Grade Criteria
0 Fully active, performs at predisease level
1 Activity less than predisease level; able to function as
acceptable pet
2 Severely compromised activity; ambulatory only to point
of eating,
sleeping, and consistently eliminating in acceptable areas.
3 Completely disabled; must be force fed; unable to defecate
or urinate
in acceptable areas
4 Deadchlorambucil at the dose of 4 mg/m2 and piroxicam at
the dose of 0.3 mg/kg EOD due to metabolic differences
between the two species and the easier administration
of chlorambucil to cats. At presentation patients were
valuated accordingly to a modified Karnofsky performance
scale (Table 1). Toxicity was defined as disease processes
that occurred secondary to therapy and accordingly scored
(Table 2). Gastro-intestinal toxicity was scored accordinglyDiarrhea
0 None
1 Soft stools, responds to dietary modification
2 1–4 watery stools per day, <2 days
3 4–7 watery stools per day or >2 days
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[26,30]. In order to have the best assessment of therapy
toxicoses, after every therapy owners were sent home with
a questionnaire to be completed in order to record pos-
sible gastrointestinal side effects of the protocol (Table 3).
Response to treatment was assessed on the basis of clinical
evaluation and confirmatory biopsies. Response to treat-
ment in terms of toxicity and tumor response were assessed
prior each therapy. At that time a physical exam and tumor
measure were performed. Moreover thoracic radiographs
and abdominal ultrasonography were performed every two
months to check for tumor spread. Tumor response was
defined as follows:
Complete Remission (CR) - the disappearance of all
evidence of cancer in all sites for a defined period of time.
Partial Remission (PR) - the decrease in size of all
tumors by 50% or greater as measured by the sum of
the product of two diameters of each tumor for a
defined period of time.
Stable Disease (SD) - the decrease of <50% or an
increase of < 25% in the sum of the product of two
diameters for a defined period of time.
Progressive Disease (PD) - the increase of 25% or
more in the sum of the product of two diameters for a
defined period of time.
No evidence of disease – absence of tumor growth
(local recurrence or distant metastases) after surgeryTable 3 Daily evaluation form sent home and made out by th
Vomiting
None 3 episodes per day 5 episodes per day
OR OR
vomiting lasting 2 days vomiting lasting 4 day
Diarrhea
None 2 more stools 6 more stools
than normal than normal
Nausea
None Appetite loss with Salivating or lip
normal eating habits smacking for 12 hrs
Appetite
Normal With treats or diet Appetite loss for 3 days
change, ate 100% With treats or diet
change, ate 50% of norm
Flatulence
Normal 1-2 episodes per day 2-4 episodes per day
Activity
Normal Mild lethargy Moderate lethargy, diffic
with daily activitiesfor highly metastatic tumors, following PPI and
chemotherapy for a defined period of time.
Statistical analysis
Response to treatment was assessed using the median
time to terminal event and its 95% confidence interval.
The terminal event was tumor progression, recurrence or
death attributable to cancer or other non-cancer causes.
Time to recurrence was defined as time from the observa-
tion of tumor disappearance and estimated according to the
Kaplan-Meier method [31]. The statistical significance of
the differences in survival distribution among the treatment
groups (experimental versus control) was evaluated by the
log-rank test [32]. P values <0.05 were regarded as signifi-
cant in two-tailed tests. SPSS software (version 10.00 SPSS
Chicago) was used for statistical analysis.
Evaluation of patients
Finally, the owners were questioned prior to each therapy
on the activity level, performance status and food and water
consumption of their animals. Patients had a complete
hematological and biochemical analysis performed every
two weeks, while thoracic radiographs and ultrasonogra-
pic exam were scheduled to be performed at 1, 3, 5, 7, 9,
12, 18 months, together with a physical evaluation. More-
over, owner have been interviewed regarding their degree
of satisfaction regarding the treatments. This was made as
a surrogate for the psychological aspects of chemotherapye owners
>5 episodes per day >5 per day OR
OR days lasting >4 days and
s for >4 days life threatening
>6 more stools >6 and life
than normal hospitalized
Salivation or lip Salivation/lip
smacking for 24 hrs smacking >24 h
OR Appetite loss for 5 days OR Loss >5 days
With treats or diet OR
al change, ate few bites No interest,
no appetite
4-6 episodes per day > 6 episodes per day
ulty Severe lethargy, only Unable to
gets up to go outside rise on own
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the treatment. Indeed, while Treatment were scheduled to
be continued until a complete remission or an absence of
disease was observed for one year, a maintenance schedule
was devised for the long term responders. At that time
chemotherapy was discontinued while therapy with lanso-
prazole and patient alkalization were continued as a main-
tenance protocol.
Results
Twenty-four pets affected by different solid tumors were
enrolled in the study (twenty-two dogs and two cats)
over a 30 months period. There were 11 male dogs and
11 female dogs, most of whom where spayed while the
two cats were both female. Age ranged from 6 to 13 years.Table 4 Patients characteristics and outcome of 24 pets with
and alkalization
Patient Age Sex Tumor
Mixed breed 10 FS Metastatic Anal sac Ca (sublumbar lymp
Mixed breed 12 FS Metastatic Anal sac Ca (sublumbar lymp
Mixed breed 16 FS Thyroid Ca
Cocker Spaniel 6 MC Liver Sarcoma
Dachshund 13 MC Liver Ca
Golden retriever 14 MC Ruptured
Splenic HSA
Labrador retriever 12 MC Ruptured
Splenic HSA
Golden retriever 13 FS Recurring inflammatory mammary Ca
Golden retriever 10 FS Recurring inflammatory mammary Ca
Boxer 10 FS Metastatic mammary Ca (axillary lymph
Dachshund 13 MC Limb Sarcoma
Labrador retriever 11 M Recurring
Neck Sarcoma
Mixed breed 13 FS Nasal sinus AdCa
Labrador 10 FS Nasal Sarcoma
Tibetan spaniel 11 M Nasal carcinoma
Visla 10 M Nasal carcinoma
Mixed breed 10 F Lingual SCC
Mixed breed 12 FS Lung carcinoma
Mixed breed 13 F Lung carcinoma
German Shepherd 10 M Visceral histiocytosis
German shepherd 9 M OSA
Rottweiler 8 M OSA
DSH 10 FS Nasal CSA
DSH 10 FS Recurring anaplastic mammary carcinom
The tumor stage refers at the moment of referral. HSA patients were referred af
without gross disease.
Abbreviations: CA carcinoma, CR complete remission, CSA chondrosarcoma, F female
OSA osteosarcoma, PD progressive disease, PR partial remission, SCC squamous cellPatients characteristics and response to therapy are shown
in Table 4. Eight patient had previous surgery for their pri-
mary tumors (six of them had either regional metastases
or local recurrence when referred for therapy) and one had
three sessions of electrochemotherapy resulting in partial
remission of the tumor. This last patient then switched to
metronomic chemotherapy for financial reasons and
further improved the tumor response. None of the pa-
tients with metastatic disease had metastasectomy per-
formed prior to referral, having all the owners elected
their pets to be pharmacologically treated. The only
patients that has no evidence of disease at the time of
referral were four patients with ruptured splenic heman-
giosarcoma (two per each cohort) that have been enrolled
in the survival study in consideration of the extremely highadvanced cancer treated with metronomic chemotherapy
Prev. treatment Tumor stage Outcome (weeks)
h nodes) Surgery T0 N1 MX PR 40
h nodes) Surgery T0 N1 MX CR 56
Biopsy T3B N0 MX PD
Biopsy T2 N0 MX PR 30
Biopsy T2 N0 MX CR 90+
Surgery T3 N0 MX NED 72
Surgery T3 N0 MX NED 34
Surgery T4 N0 MX CR 104+
Surgery T4 N0 MX PD
node) Biopsy T3 N1 MX PR 32
Biopsy T3 N0 MX CR 20
Surgery T2 N0 MX NED 30
Biopsy T3 N0 MX PR 24+
Electrochemotherapy T3 N0 MX PR 20+
Biopsy T3 N0 MX PR 8
Biopsy T2 N0 MX PR16+
Biopsy T2 N1A MX PR 16+
Biopsy T1 NX MX SD 16+
Biopsy T1 NX MX PR 12
Biopsy T3 N1 MX PD
Biopsy T2 NX MX PD
Biopsy T2 NX MX SD 8+
Biopsy T2 N0 MX PR 100
a Surgery T4 N0 MX NED 54+
ter the surgical removal of their ruptured spleen and were the only patients
, FS female spayed, M male, MC male castrated, NED no evidence of disease,
carcinoma, SD stable disease.
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lation. All the four patients begun their medical therapy
two weeks after splenectomy. Survival time was calculated
from the beginning of metronomic chemotherapy. The
historical control group consisted with 10 dogs affected by
different neoplasms whose characteristics are summarized
in Table 5. In this group there were 6 females and 4 males
who tolerated the metronomic therapy without side effects.
The combination of metronomic chemotherapy and alkal-
izing treatment was overall well tolerated, one dog had mild
diarrhea but continued the therapy albeit at a decreased
lansoprazole dose (2 mg/kg in the three loading days).
Two dogs had vomiting that resulted in lansoprazole re-
duction from 5 mg/kg to 3 mg/kg. Finally 8 dogs out of
22 experienced different degrees of flatulence that par-
tially improved with the addition of probiotics to their
diet. The overall responses rate was 75%, including 4
complete remissions, 10 partial responses, 4 no evidence
of disease (adjuvant therapy group), 2 stable diseases and
4 progressive diseases. On the other hand, the overall
response rate in the control group was 40% with two
short lived NEDs in dogs with highly metastatic cancers,
one PR in a dog with a ulnar OSA that recurred after par-
tial ulnectomy and one long lasting CR in a dog with an
inflammatory mammary carcinoma. In this cohort only one
patient out of ten experienced a complete long lasting re-
sponse, while all the other were non responders or short
lived responders. Figure 1 shows two patients that success-
fully responded to the therapy while Figure 2 shows a stable
disease in a dog with a large lung tumor. At the time of
writing a total of 9 patients (8 dogs and 1 cat) are still alive
and periodically monitored leading to a survival rate ofTable 5 Patients characteristics and outcome of 10 pets with ad
Patient Age Sex Tumor
Mixed breed 13 FS Metastatic
Anal sac Ca (sublumbar lymph node
Poodle 12 MC Thyroid Ca
Labrador 9 F Liver CA
Golden retriever 11 MC Ruptured
Splenic HSA
German Shepherd 10 MC Ruptured
Splenic HSA
Boxer 11 FS Inflammatory mammary Ca
Mixed breed 13 FS Recurring
Inflammatory mammary Ca
Boxer 10 FS Mammary Ca
Doberman 13 FS Anaplastic mammary Ca (axillary lym
Boxer 11 M C OSA
Abbreviations: CA carcinoma, CR complete remission, F female, FS female spayed, M
PD progressive disease, PR partial remission.37.5% while only one control patient is still alive with a sur-
vival rate of 10%. The mean time to terminal event was
48 weeks in the experimental cohort and 18 weeks in the
control group, median time to terminal event was 34 weeks
versus 2. Figure 3 shows the Kaplan-Meier survavial curve
for the two groups. In general, the owners of the experi-
mental group reported increased activity level as well as
food and water consumption and improved quality of life.
Questioning the owners regarding their degree of satisfac-
tion with the outcome of the therapy yielded a total of 90%
of appreciation in the PPI group and a 40% in the control
group. Appreciation was greatly influenced on the pets
moving up in the karnofsky scale as a consequence of im-
proved response and degree of side effects and ranged from
“somewhat satisfied” to “enthusiastic”. Figure 4 summarizes
the degree of satisfaction among the different groups of
owners. While tumor control was the major issue in the
control group, in the PPI cohort, as a consequence of a bet-
ter clinical outcome, the major causes of complains were
the gastrointestinal side effects (specifically the flatulence)
experienced by some dogs rather than the degree of tumor
response. The management of these complications through
diet and integration with probiotics greatly improved the
owners degree of satisfaction.
Conclusions
The proton pump inhibitor lansoprazole, administered at
high dose and combined with a water alkalizer, has proven
to enhance tumor response to metronomic chemotherapy,
increasing the number of complete responders [4] and
significantly delaying the onset of metastases in pets with
highly metastasizing neoplasms. This is a very promisingvanced cancer treated with metronomic chemotherapy alone
Prev. treatment Tumor stage Outcome (weeks)
Surgery T0 N1 MX PD
s)
Biopsy T3B N0 MX PD
Biopsy T2 N0 MX PD
Surgery T3 N0 MX NED 28
Surgery T3 N0 MX NED 20
Biopsy T4 N0 MX CR 80+
Surgery T4 N0 MX PD
Biopsy T3C N1 MX PD
ph node) Biopsy T3B N1 MX PD
Biopsy T2 NX MX PR 40
male, MC male castrated, NED no evidence of disease, OSA osteosarcoma,
Figure 1 A canine patient with a nasal sarcoma at presentation (A) and after 4 months of therapy (B), the dog had a nasal sinus
sarcoma that underwent PR resulting in cessation of nasal discharge and bleeding as well as pawing at the lesion. Another patient with
a large ulcerated high grade mammary carcinoma (C) experiencing a long lasting PR (D).
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low number of patients experiencing complete responses
as well as the difficulty to have a significant delay for the
onset of metastatic disease in patients with advanced can-
cer [10-17]. The broad spectrum of solid tumors that
responded to this clinical approach including two patients
with metastasized anal sac carcinoma makes this combin-
ation extremely promising. Of course this study had some
limitations due to the lack of tumor homogeneity in our
two cohorts. This bias can’t be overcome, inasmuch pets
with advanced cancer stage suitable to be included to thisFigure 2 A canine patient with lung cancer treated with metronomic
months control (B).study presented tumors that very often varied in their his-
tologies. Moreover, the owners of the pets affected with
advanced cancer were particularly available in trying new
approached being well aware of the disease in their
companion animals and of their expected poor progno-
sis. Notably, although the level of cancer progression
and the size of the cancer, we observed a clear improve-
ment of the clinical response to the metronomic therapy
when combined with an alkalinizing treatment, inde-
pendently from the nature of cancer, suggesting that
systemic alkalinisation might represent one of the mostchemotherapy and alkalization at presentation (A) and at four
Figure 3 Kaplan-Meier survival curve for alkalized patients (red line) and controls (blue line).
Figure 4 Histogram representation of the owners’ percentage and degree of satisfaction for the clinical outcome of their pets in the
PPI and control groups.
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much as tumor extracellular acidity is a feature com-
mon to all cancers. This is for sure a novelty in the
clinical management of cancer patients that should be
taken into careful account in the future anti-cancer
strategies. Of course our study lacked a system to assess
the in vivo pH changes as well; this was due to the absence
of pH measurement methodology approved for the
clinical use but also to the financial constrains to an
observational setting. In order to improve the protocol
and to identify prognostic factors, steps should be made
to measure changes in tumor pH during the therapy in
order to monitor progresses and also to have a param-
eter to be monitored in order to identify escape from
medical control. Furthermore, a reliable and portable
system to quantify variation in growth factors involved
in tumor progression and angiogenesis should be devised
[17]. The combination of water alkalinisation and high
dosage proton pump inhibitors has been shown to effect-
iveness of metronomic therapy on tumour progression,
but also to highly improve the quality of life of pets affected
by spontaneous malignant tumors. In particular the animals
did not show to refuse the alkalinized water, while occa-
sional experience in human patients showed that sodium
bicarbonate may not be administered for a long period of
time, inasmuch as patients very often refused it. Notably,
while this study allowed to try with a real experimental clin-
ical approach against advanced cancer, it did not allow to
quantify the exact contribution of PPIs and alkalized water
to the increased efficacy of metronomic chemotherapy,
while alkalinizing approaches using sodium bicarbonate
suggest a potential efficacy of water alkalinisation in cancer
treatment [33]. Further studies will be mandatory to evalu-
ate the effects of single alkalinizing approaches as potential
anti-cancer treatments . In our study the owners of the pet
included in the experimental group provided the emotional
component and a daily evaluation of the quality of life, pro-
viding a rough estimate of the patient toleration of the
therapeutic regimen, allowing the investigators to work in a
close approximation of the human clinical condition. More-
over, sodium bicarbonate is an unbalanced buffer with only
sodium as an oligoelement, and this may raise cardiovascu-
lar problems in long term administrations. The inclusion of
multiple drugs affecting tumor acidity is highly desirable in
order to develop multidrug protocols to increase cancer
control [33]. Finally, there is accumulating evidence also in-
dicating that some metronomic regimens might be able to
promote disease eradication by stimulating anticancer im-
mune and selectively eliminating immunosuppressive cells
[9,15]. The increased anti-tumor immune response by pro-
ton pump inhibitors has been clearly shown [34,35], and
the overall response to the combination of proton pump in-
hibitors, alkalinized water and metronomic therapy, suggest
that this approach may be highly helpful in the generalizedresponse of the body against cancer. Further investigations
are clearly warranted also in this perspective to assess the
weight of the immune component in the long term control
of tumors in patient undergoing alkalizing metronomic
chemotherapy [35].
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